title: Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer.
authors.affiliation: Department of Biotechnology and Life Sciences, Section of Medical and Surgical Sciences, Università degli Studi dell'Insubria, Busto A., Varese, Italy; Department of Basic Medical Sciences, Ghent University, Ghent. gianpaolo.perletti@uninsubria.it.
authors.forename: Gianpaolo
authors.initials: G
authors.lastname: Perletti
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*